<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-2-9</article-id><article-id pub-id-type="pmid">11560764</article-id><article-id pub-id-type="doi">10.1186/1471-2350-2-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>ApoE</italic> polymorphisms in narcolepsy</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Gencik</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>martin.gencik@ruhr-uni-bochum.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Dahmen</surname><given-names>Norbert</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>ndahmen@mail.psychiatrie.klinik.uni-mainz.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Wieczorek</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stefanwieczorek@web.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Kasten</surname><given-names>Meike</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>meike.kasten@t-online.de</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Gencikova</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alexandra@gencik.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Epplen</surname><given-names>Jorg T</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>joerg.t.epplen@ruhr-uni-bochum.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Molecular Human Genetics, Ruhr-University, D-44780 Bochum, Germany</aff><aff id="I2"><label>2</label>Psychiatrische Klinik der Johannes-Gutenberg-Universitat, Mainz, Germany</aff><pub-date pub-type="collection"><year>2001</year></pub-date><pub-date pub-type="epub"><day>9</day><month>8</month><year>2001</year></pub-date><volume>2</volume><fpage>9</fpage><lpage>9</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/2/9"/><history><date date-type="received"><day>13</day><month>6</month><year>2001</year></date><date date-type="accepted"><day>9</day><month>8</month><year>2001</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2001 Gencik et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2001</copyright-year><copyright-holder>Gencik et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title>Background</title><p>Narcolepsy is a common neuropsychiatric disorder characterized by increased daytime sleepiness, cataplexy and hypnagogic hallucinations. Deficiency of the hypocretin neurotransmitter system was shown to be involved in the pathogenesis of narcolepsy in animals and men. There are several hints that neurodegeneration of hypocretin producing neurons in the hypothalamus is the pathological correlate of narcolepsy. The <italic>ApoE4</italic> allele is a major contributing factor to early-onset neuronal degeneration in Alzheimer disease and other neurodegenerative diseases as well.</p></sec><sec sec-type="methods"><title>Methods</title><p>To clarify whether the ApoE4 phenotype predisposes to narcolepsy or associates with an earlier disease onset, we have genotyped the <italic>ApoE</italic> gene in 103 patients with narcolepsy and 101 healthy controls.</p></sec><sec><title>Results</title><p>The frequency of the E4 allele of the <italic>ApoE</italic> gene was 11% in the patient and 15% in the control groups. Furthermore, the mean age of onset did not differ between the ApoE4<sup>+</sup> and ApoE4<sup>-</sup> patient groups.</p></sec><sec><title>Conclusion</title><p>Our results exclude the <italic>ApoE4</italic> allele as a major risk factor for narcolepsy.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Narcolepsy is a frequent debilitiating neuropsychiatric disorder characterized by increased daytime sleepiness, cataplectic episodes and hypnopompic and hypnagogic hallucinations. The occurence of narcolepsy is sporadic; however, a proportion of cases is familial with an autosomal-dominant type of inheritance. In contrast to the normal population with an <italic>HLA-DR2</italic> allele frequency of &#x0223c;30%, over 90% of narcoleptics type <italic>HLA-DR2</italic><sup>+</sup> and <italic>HLA-DQB1*0602</italic><sup>+</sup>[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The biological significance of this association remains elusive implicating autoimmune aspects in the ethiology [<xref ref-type="bibr" rid="B3">3</xref>]. In two animal models the involvement of the hypocretin (orexin) neurotransmitter system was demonstrated. Murine narcolepsy induced by knocking out the <italic>hypocretin</italic> gene shows symptoms corresponding to human narcolepsy [<xref ref-type="bibr" rid="B4">4</xref>]. Dobermann pincher and Labrador breeds with autosomal recessively inherited narcolepsy each share a splice-site mutation in the <italic>hypocretin-receptor 2</italic> gene [<xref ref-type="bibr" rid="B5">5</xref>]. Although hypocretin levels in CSF of most narcoleptics is <italic>decresed</italic> or not detectable [<xref ref-type="bibr" rid="B6">6</xref>], no causative mutations in both <italic>hypocretin receptor</italic> genes were found in humans. A single patient with atypical early-onset narcolepsy carries a dominant signal peptide mutation in the <italic>preprohypocretin</italic> gene [<xref ref-type="bibr" rid="B7">7</xref>]. Furthermore a rare sequence variant in the 5'UTR of <italic>preprohypocretin</italic> gene has been shown to be a risk factor for narcolepsy [<xref ref-type="bibr" rid="B8">8</xref>]. Recent reports describe a nearly complete loss of hypocretinergic neurons in brains of narcoleptic patients as well as scar tissue normally occupied by the hypocretin-producing cells [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Among several neurodegenerative diseases the <italic>E4</italic> allele of the <italic>ApoE</italic> gene has been recognized as a predisposing genetic risk factor mainly influencing the age of manifestation of M. Alzheimer. The ApoE protein is a component of the VLDL particles and chylomicrons and its primary role is lipid transport [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. The pathophysiological effect of <italic>ApoE4</italic> in neurodegeneration is not clarified yet and may possibly involve diminished neuroprotection against amyloid depositions, reactive oxygen species or exitotoxins [<xref ref-type="bibr" rid="B12">12</xref>]. We have tested the hypothesis of the involvement of the <italic>E4</italic> allele of ApoE in the etiology of narcolepsy.</p></sec><sec sec-type="methods"><title>Methods</title><p>Patients were recruited from the University Hospital in Mainz and St. Josef Hospital in Bochum, Germany. All but two patients suffered from cataplexies. All patients fulfilled diagnostic criteria of the <italic>Diagnostic and Statistical Manual of Mental Disorders,</italic> 4th edition (DSM IV) and the International Classification of Sleep Disease of the American Sleep Disorders Association for narcolepsy. For further details see Gencik <italic>et al.</italic> 2000 [<xref ref-type="bibr" rid="B8">8</xref>]. The control group was composed of neurologically investigated 101 healthy individuals. All participants gave written, informed consent.</p><p><italic>ApoE</italic> genotyping was performed as described [<xref ref-type="bibr" rid="B13">13</xref>]. The HLA-DR2 status of the patients was determined previously. 94 patients typed HLA-DR2<sup>+</sup> and 9 patients HLA-DR2<sup>-</sup>[<xref ref-type="bibr" rid="B8">8</xref>]. Genotype and allele frequencies were compared with the &#x003a7;<sup>2</sup>-significance test. The age of onset was known in 60 patients with E4<sup>-</sup> genotypes and 13 patients with E4<sup>+</sup>genotypes, these data were compared by the Mann Whitney test.</p></sec><sec><title>Results and discussion</title><p>Until now, only a few factors were recognized to predispose to narcolepsy. It is the major association with the <italic>HLA-DR2</italic> allele on the one hand. Specific <italic>TNF</italic>&#x003b1; alleles [<xref ref-type="bibr" rid="B14">14</xref>] as well as the 3250T allele of the <italic>preprohypocretin</italic> gene [<xref ref-type="bibr" rid="B8">8</xref>] are minor contributors to the etiology on the other hand. No exogenous risk factors for narcolepsy have been recognized so far.</p><p>Recently, a novel neurotransmitter system was shown to be involved in narcolepsy in the canine disease model and in the orexin knock-out mouse. Autopsy reports of narcoleptic dogs and patients with narcolepsy pointed out possible neurodegenerative processes in areals with hypocretin-producing neurons. Taken together, the pathophysiology of narcolepsy seems to involve an autoimmune driven neurodegeneration of yet unkown cause [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B15">15</xref>].</p><p>In order to specify the role of ApoE isoforms in narcolepsy, we have determined the allele and genotype frequencies of the <italic>E2</italic>, <italic>E3</italic> and <italic>E4</italic> alleles in patients with narcolepsy and healthy controls. Allelic and genotypic frequencies are shown in table <xref ref-type="table" rid="T1">1</xref>. No statistically significant differences were detected between nacoleptics, the DR2 subgroups and the controls. Although not significant, a tendentially increased E3 frequency was seen among the DR2<sup>+</sup> subgroup of narcoleptics. Furthermore, in 73 narcoleptics exact age of onset could be determined. 60 patients had an non-E4, 13 patients had an E4 phenotype. The manifestation ages were 19.6 &#x000b1; 9.9 years (mean &#x000b1; SD) and 21.4 &#x000b1; 8.6 years for the non-E4 group and E4 group, respectively. The mean difference of 1.8 years were not statistically signifcant (p = 0.44).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Allele and genotype frequencies of the <italic>ApoE</italic> gene in narcolespy patients and controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>Patients (n = 103)</bold></td><td align="left"><bold>DR2<sup>+</sup> (n = 94)</bold></td><td align="left"><bold>DR2<sup>-</sup> (n = 9)</bold></td><td align="left"><bold>Controls (n = 91)</bold></td></tr></thead><tbody><tr><td align="left">Alleles</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">E2</td><td align="left">8%(16)</td><td align="left">7.5% (14)</td><td align="left">11% (2)</td><td align="left">10%(18)</td></tr><tr><td align="left">E3</td><td align="left">82%(168)</td><td align="left">83%(155)</td><td align="left">72%(13)</td><td align="left">75%(136)</td></tr><tr><td align="left">E4</td><td align="left">11%(22)</td><td align="left">10%(19)</td><td align="left">17%(3)</td><td align="left">15%(28)</td></tr><tr><td align="left">Genotypes</td><td></td><td></td><td></td><td></td></tr><tr><td align="left">E2/E3</td><td align="left">14%(14)</td><td align="left">14%(13)</td><td align="left">11%(1)</td><td align="left">18%(16)</td></tr><tr><td align="left">E2/E4</td><td align="left">2%(2)</td><td align="left">1%(1)</td><td align="left">11%(1)</td><td align="left">2%(2)</td></tr><tr><td align="left">E3/E3</td><td align="left">66%(68)</td><td align="left">67%(63)</td><td align="left">56%(5)</td><td align="left">55%(50)</td></tr><tr><td align="left">E3/E4</td><td align="left">18%(18)</td><td align="left">17%(16)</td><td align="left">22%(2)</td><td align="left">22%(20)</td></tr><tr><td align="left">E4/E4</td><td align="left">1%(1)</td><td align="left">1%(1)</td><td align="left">/</td><td align="left">3%(3)</td></tr></tbody></table></table-wrap></sec><sec><title>Conclusion</title><p>The presented results indicate, that the E4 isotype of the ApoE protein, which is an important risk factor for complex traits like alzheimer disease, parkinsonism and other neurodegenerative disorders is not involved in pathophosiological processes in narcolepsy.</p></sec><sec><title>Declaration of competing interests</title><p>None declared.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/content/backmatter/1471-2350-2-9-b1.pdf"/></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="other"><article-title>0MIM 161400</article-title></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mignot</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Rogers</surname><given-names>W</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Okun</surname><given-names>M</given-names></name><name><surname>Hohjoh</surname><given-names>H</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name><name><surname>Hsu</surname><given-names>S</given-names></name><name><surname>Leffell</surname><given-names>M</given-names></name><name><surname>Grumet</surname><given-names>F</given-names></name><name><surname>Fernandez-Vina</surname><given-names>M</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Risch</surname><given-names>N</given-names></name></person-group><article-title>Complex HLA-DR and &#x02013; DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><fpage>686</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">11179016</pub-id><pub-id pub-id-type="doi">10.1086/318799</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mignot</surname><given-names>E</given-names></name><name><surname>Thorsby</surname><given-names>E</given-names></name></person-group><article-title>Narcolepsy and the HLA system.</article-title><source>N EngI J Med</source><year>2001</year><volume>344</volume><fpage>692</fpage><pub-id pub-id-type="pmid">11229347</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200103013440918</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chemelli</surname><given-names>RM</given-names></name><name><surname>Willie</surname><given-names>JT</given-names></name><name><surname>Sinton</surname><given-names>CM</given-names></name><name><surname>Elmquist</surname><given-names>JK</given-names></name><name><surname>Scammell</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Kisanuki</surname><given-names>Y</given-names></name><name><surname>Fitch</surname><given-names>TE</given-names></name><name><surname>Nakazato</surname><given-names>M</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>CB</surname><given-names>Staper</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name></person-group><article-title>Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.</article-title><source>Cell</source><year>1999</year><volume>98</volume><fpage>437</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">10481909</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Faraco</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Kadotani</surname><given-names>H</given-names></name><name><surname>Rogers</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>de Jong</surname><given-names>PJ</given-names></name><name><surname>Nishino</surname><given-names>S</given-names></name><name><surname>Mignot</surname><given-names>E</given-names></name></person-group><article-title>The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.</article-title><source>Cell</source><year>1999</year><volume>98</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">10458611</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>S</given-names></name><name><surname>Ripley</surname><given-names>B</given-names></name><name><surname>Overeem</surname><given-names>S</given-names></name><name><surname>Lammers</surname><given-names>GJ</given-names></name><name><surname>Mignot</surname><given-names>E</given-names></name></person-group><article-title>Hypocretin (orexin) deficiency in human narcolepsy.</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>39</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10615891</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(99)05582-8</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peyron</surname><given-names>C</given-names></name><name><surname>Faraco</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>W</given-names></name><name><surname>Ripley</surname><given-names>B</given-names></name><name><surname>Overeem</surname><given-names>S</given-names></name><name><surname>Charnay</surname><given-names>Y</given-names></name><name><surname>Nevsimalova</surname><given-names>S</given-names></name><name><surname>Aldrich</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>D</given-names></name><name><surname>Albin</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Hungs</surname><given-names>M</given-names></name><name><surname>Pedrazzoli</surname><given-names>M</given-names></name><name><surname>Padigaru</surname><given-names>M</given-names></name><name><surname>Kucherlapati</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Maki</surname><given-names>R</given-names></name><name><surname>Lammers</surname><given-names>GJ</given-names></name><name><surname>Bouras</surname><given-names>C</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name><name><surname>Nishino</surname><given-names>S</given-names></name><name><surname>Mignot</surname><given-names>E</given-names></name></person-group><article-title>A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>991</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">10973318</pub-id><pub-id pub-id-type="doi">10.1038/79690</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gencik</surname><given-names>M</given-names></name><name><surname>Dahmen</surname><given-names>N</given-names></name><name><surname>Wieczorek</surname><given-names>S</given-names></name><name><surname>Kasten</surname><given-names>M</given-names></name><name><surname>Bierbrauer</surname><given-names>J</given-names></name><name><surname>Anghelescu</surname><given-names>II</given-names></name><name><surname>Szegedi</surname><given-names>A</given-names></name><name><surname>Menezes Saecker</surname><given-names>AM</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name></person-group><article-title>A prepro-orexin gene polymorphism is associated with narcolepsy.</article-title><source>Neurology</source><year>2000</year><volume>56</volume><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">11148249</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thannickal</surname><given-names>TC</given-names></name><name><surname>Moore</surname><given-names>RY</given-names></name><name><surname>Nienhuis</surname><given-names>R</given-names></name><name><surname>Ramanathan</surname><given-names>L</given-names></name><name><surname>Gulyani</surname><given-names>S</given-names></name><name><surname>Aldrich</surname><given-names>M</given-names></name><name><surname>Cornford</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>JM</given-names></name></person-group><article-title>Reduced number of hypocretin neurons in human narcolepsy.</article-title><source>Neuron</source><year>2000</year><volume>27</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">11055430</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahley</surname><given-names>RW</given-names></name><name><surname>Rall</surname><given-names>SC</given-names></name></person-group><article-title>Apolipoprotein E: Far more than a lipid transport protein.</article-title><source>Annu Rev Genomics Hum Genet</source><year>2000</year><volume>01</volume><fpage>507</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">11701639</pub-id><pub-id pub-id-type="doi">10.1146/annurev.genom.1.1.507</pub-id></citation></ref><ref id="B11"><citation citation-type="other"><article-title>OMIM 107741</article-title></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahley</surname><given-names>RW</given-names></name><name><surname>Huanng</surname><given-names>Y</given-names></name></person-group><article-title>Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond.</article-title><source>Curr Opin Lipol</source><year>1999</year><volume>10</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1097/00041433-199906000-00003</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>R</given-names></name><name><surname>Vieira-Saecker</surname><given-names>AM</given-names></name><name><surname>Kuhn</surname><given-names>W</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Muller</surname><given-names>T</given-names></name><name><surname>KuhnI</surname><given-names>N</given-names></name><name><surname>Fuchs</surname><given-names>GA</given-names></name><name><surname>Storch</surname><given-names>A</given-names></name><name><surname>Hungs</surname><given-names>M</given-names></name><name><surname>Woitalla</surname><given-names>D</given-names></name><name><surname>Przuntek</surname><given-names>H</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name><name><surname>Schols</surname><given-names>L</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name></person-group><article-title>Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype.</article-title><source>Ann Neurol</source><year>1999</year><volume>45</volume><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">10319883</pub-id><pub-id pub-id-type="doi">10.1002/1531-8249(199905)45:5&#x0003c;611::AID-ANA9&#x0003e;3.3.CO;2-O</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hohjoh</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>J</given-names></name><name><surname>Miyagawa</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Akaza</surname><given-names>T</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Juji</surname><given-names>T</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name></person-group><article-title>Significant association of a single nucleotide polymorphism in the tumor necrosis factor-alpha (TNF-alpha) gene promoter with human narcolepsy.</article-title><source>Tissue Antigens</source><year>1999</year><volume>54</volume><fpage>138</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">10488740</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-0039.1999.540204.x</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinze-Selch</surname><given-names>D</given-names></name><name><surname>Wetter</surname><given-names>TC</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>HC</given-names></name><name><surname>Albert</surname><given-names>ED</given-names></name><name><surname>Mullington</surname><given-names>J</given-names></name><name><surname>Wekerle</surname><given-names>H</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name><name><surname>Pollmacher</surname><given-names>T</given-names></name></person-group><article-title>In vivo and in vitro variables in patients with narcolepsy and HLA-DR2 matched controls.</article-title><source>Neurology</source><year>1998</year><volume>50</volume><fpage>1149</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">9566413</pub-id></citation></ref></ref-list></back></article> 